Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer - A Systematic Review

Overview

Journal Breast Cancer (Auckl)

Publisher Sage Publications

Date 2022 Mar 28

PMID 35340888

Authors

Matthew G Davey

Martin S Davey

Vinitha Richard

William Wyns

Osama Soliman

Nicola Miller

Aoife J Lowery

Michael J Kerin

Affiliations

Soon will be listed here.

Abstract

Purpose: Increased appreciation of the human epidermal growth factor receptor-2 (HER2/neu) signalling pathway has led to the development of targeted therapeutic agents used in conjunction with chemotherapy to improve outcomes for HER2 overexpressing (HER2+) breast cancer. For neoadjuvant therapy, response rates can be unpredictable - novel biomarkers predicting effectiveness are required to enhance oncological outcomes for these patients, and microRNA may prove effective. Our objective was to identify microRNA (miRNA) expression patterns predictive of response to neoadjuvant chemotherapy (NAC) and/or anti-HER2 targeted therapies in patients being treated for early-stage HER2+ breast cancer.

Methods: A search was performed of the PUBMED, SCOPUS, Web of Science, and EMBASE in accordance to Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.

Results: Overall, 15 studies including 1335 patients were included. These studies highlighted an expression profile of 73 miRNA and their ability to predict tumour response to neoadjuvant therapies was correlated. Results from 11 studies were in relation to circulatory miRNA and 4 studies included data from tumour tissue. Overall, upregulation and downregulation of 41 miRNA and 29 miRNA, respectively, predicted differential response to neoadjuvant therapy. Expression levels of 3 miRNA (miR-21, miR-210, and miR-376c-3p) were inconclusive in predicting therapeutic response, while 'aberrant' expression of circulating miR-199a predicted pathological complete response (pCR) to NAC.

Conclusions: This systematic review outlines expression patterns of a number of miRNA which correlate with response to NAC and/or anti-HER2 therapies. Future translational research evaluating predictive biomarkers of primary response to neoadjuvant therapy in HER2+ breast cancer may consider these results.

Citing Articles

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer.

Haussmann J, Budach W, Nestle-Kramling C, Wollandt S, Jazmati D, Tamaskovics B Radiat Oncol. 2024; 19(1):99.

PMID: 39085866 PMC: 11293047. DOI: 10.1186/s13014-024-02450-5.

Biological Implications of MicroRNAs as Regulators and Biomarkers of Therapeutic Toxicities in Breast Cancer.

Abbas Syed R, Davey M, Richard V, Miller N, Kerin M Int J Mol Sci. 2023; 24(16).

PMID: 37628874 PMC: 10454054. DOI: 10.3390/ijms241612694.

Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis.

Tiberio P, Gaudio M, Belloni S, Pindilli S, Benvenuti C, Jacobs F Cancers (Basel). 2023; 15(13).

PMID: 37444533 PMC: 10340268. DOI: 10.3390/cancers15133424.

Assessing the Role of MicroRNAs in Predicting Breast Cancer Recurrence-A Systematic Review.

Mkabaah L, Davey M, Lennon J, Bouz G, Miller N, Kerin M Int J Mol Sci. 2023; 24(8).

PMID: 37108278 PMC: 10138898. DOI: 10.3390/ijms24087115.

The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy.

Lisencu L, Roman A, Visan S, Bonci E, Pasca A, Grigorescu E Medicina (Kaunas). 2022; 58(10).

PMID: 36295655 PMC: 9608077. DOI: 10.3390/medicina58101494.

References

Stevic I, Muller V, Weber K, Fasching P, Karn T, Marme F . Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018; 16(1):179. PMC: 6178264. DOI: 10.1186/s12916-018-1163-y. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z . Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 2011; 34(12):675-80. DOI: 10.1159/000334552. View

Selcuklu S, Donoghue M, Rehmet K, de Souza Gomes M, Fort A, Kovvuru P . MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem. 2012; 287(35):29516-28. PMC: 3436132. DOI: 10.1074/jbc.M111.335943. View

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

Carey L, Berry D, Cirrincione C, Barry W, Pitcher B, Harris L . Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2015; 34(6):542-9. PMC: 4980567. DOI: 10.1200/JCO.2015.62.1268. View

Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio M, Hilbers F . Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clin Cancer Res. 2019; 25(13):3887-3895. DOI: 10.1158/1078-0432.CCR-18-2507. View

Qian P, Zuo Z, Wu Z, Meng X, Li G, Wu Z . Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 2011; 71(20):6463-74. DOI: 10.1158/0008-5472.CAN-11-1322. View

Liu B, Che Q, Qiu H, Bao W, Chen X, Lu W . Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. PLoS One. 2014; 9(1):e87563. PMC: 3909214. DOI: 10.1371/journal.pone.0087563. View

10.

Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J . The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Mol Cancer. 2019; 18(1):4. PMC: 6325825. DOI: 10.1186/s12943-018-0933-7. View

11.

Abolghasemi M, Tehrani S, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A . MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. J Cell Physiol. 2019; 235(6):5008-5029. DOI: 10.1002/jcp.29396. View

12.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

13.

Biswas T, Jindal C, Fitzgerald T, Efird J . Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. Int J Environ Res Public Health. 2019; 16(1). PMC: 6339010. DOI: 10.3390/ijerph16010124. View

14.

Huang Z, Ge H, Yang C, Cai Y, Chen Z, Tian W . MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression. Kaohsiung J Med Sci. 2019; 35(8):467-473. DOI: 10.1002/kjm2.12085. View

15.

Abolghasemi M, Tehrani S, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A . Critical roles of long noncoding RNAs in breast cancer. J Cell Physiol. 2020; 235(6):5059-5071. DOI: 10.1002/jcp.29442. View

16.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

17.

Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M . Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat. 2014; 147(1):61-8. DOI: 10.1007/s10549-014-3079-3. View

18.

Bumgarner R . Overview of DNA microarrays: types, applications, and their future. Curr Protoc Mol Biol. 2013; Chapter 22:Unit 22.1.. PMC: 4011503. DOI: 10.1002/0471142727.mb2201s101. View

19.

Son D, Kim Y, Lim S, Kang H, Kim D, Park J . miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer. Cancer Lett. 2019; 454:224-233. DOI: 10.1016/j.canlet.2019.04.006. View

20.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View